Molecular allergology place in allergen-specific immunotherapy

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Laboratory methods of allergy diagnosis are an essential tool in the allergist’s daily practice. Molecular allergodiagnostics is an advanced examination method that detects individual allergocomponent sensitization. The risk prediction of severe allergic reactions is the main area of its application, as well as the creation of personalized dietary recommendations for patients with food allergies. Clinical and anamnesis data are fundamental, supplemented by the results of traditional methods of allergy examination (skin prick tests or the specific immunoglobulin E level to whole allergens), in determining the appointment of allergen immunotherapy indications. The widespread use of such resource-intensive examination as molecular allergodiagnostics for all patients is unjustified before prescribing allergen immunotherapy. Additionally, decisions on the allergen immunotherapy continue or the termination cannot be made based on the change data in the level of clinically relevant specific IgE. Concurrently, its use as a third-line diagnostic method can help in solving difficult clinical tasks related to the identification of a causally significant allergen in patients with respiratory allergy symptoms during the seasons of the simultaneous dusting of several plants, as well as differentiate the true from the cross-sensitization in polysensitized patients. The use of molecular allergodiagnostics will be mandatory in prescribing recombinant therapeutic allergens, due to the need for a personalized choice of the drug.

作者简介

Daria Timoshenko

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

编辑信件的主要联系方式.
Email: d.o.timoshenko@gmail.com
ORCID iD: 0000-0002-7585-1390
SPIN 代码: 2714-0906

MD

俄罗斯联邦, Moscow

Ksenia Pavlova

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: ksenimedical@gmail.com
ORCID iD: 0000-0002-4164-4094
SPIN 代码: 7593-0838
Scopus 作者 ID: 7004658159
Researcher ID: P-9255-2017

MD, Cand. Sci. (Med.)

俄罗斯联邦, Moscow

Oksana Kurbacheva

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia; Moscow State University of Medicine and Dentistry named after A.I. Evdokimov

Email: kurbacheva@gmail.com
ORCID iD: 0000-0003-3250-0694
SPIN 代码: 5698-6436

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Moscow; Moscow

Natalia Ilina

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia; Moscow State University of Medicine and Dentistry named after A.I. Evdokimov; The Russian National Research Medical University named after N.I. Pirogov

Email: instimmun@yandex.ru
ORCID iD: 0000-0002-3556-969X
SPIN 代码: 6715-5650

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Moscow; Moscow; Moscow

参考

  1. Hoffmann-Sommergruber K, de las Vecillas L, Hilger C, et al. Molecular allergology user’s guide 2.0. EAACI; 2022. Available from: https://hub.eaaci.org/resources_guidelines/molecular-allergology-users-guide-2-0/. Accessed: 15.08.2022.
  2. Ansotegui I, Melioli G, Canonica G, et al. A WAO-ARIA-GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020. World Allergy Org J. 2020;13(2):100091. doi: 10.1016/j.waojou.2019.100091
  3. Barber D, Diaz-Perales A, Escribese M, et al. Molecular allergology and its impact in specific allergy diagnosis and therapy. Allergy. 2021;76(12):3642–3658. doi: 10.1111/all.14969
  4. Pomés A, Davies J, Gadermaier G, et al. WHO/IUIS Allergen Nomenclature: providing a common language. Mol Immunol. 2018;100:3–13. doi: 10.1016/J.MOLIMM.2018.03.003
  5. Russian Association of Allergists and Clinical Immunologists. Federal clinical guidelines for allergen-specific immunotherapy. Moscow; 2013. 13 p. (In Russ.)
  6. Alvaro-Lozano M, Akdis C, Akdis M, et al. EAACI Allergen immunotherapy user’s guide. Pediatr Allergy Immunol. 2020;31(S25): 1–101. doi: 10.1111/pai.13189
  7. Luengo O, Cardona V. Component resolved diagnosis: when should it be used? Clin Transl Allergy. 2014;(4):28. doi: 10.1186/2045-7022-4-28
  8. Allergen Immunotherapy Guidelines. Part 2: Recommendations. Translating knowledge into clinical practice. EAACI; 2017. Available from: https://allergiy.net/uploads/ck/Part_II_-_AIT_Guidelines_-_web_edition.pdf. Accessed: 15.08.2022.
  9. Gushchin IS, Kurbacheva OM. Allergy and allergen-specific immunotherapy. Moscow: Farmus Print Media; 2010. 228 р. (In Russ).
  10. Kozulina IE, Pavlova KS, Kurbacheva OM. Clinical efficacy of subcutaneous and sublingual allergen-specific immunotherapy of allergic rhinitis and conjunctivitis. Russian Journal of Allergy. 2016;13(6):63–69. doi: 10.36691/RJA389
  11. Ferreira F, Briza P, Infuhr D, et al. Modified recombinant allergens for safer immunotherapy. Inflamm Allergy Drug Targets. 2006;5(1):5−14. doi: 10.2174/187152806775269295
  12. Jutel M, Jaeger L, Suck R, et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005;116(3):608–613. doi: 10.1016/J.JACI.2005.06.004
  13. Pauli G, Larsen T, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008;122(5):951–960. doi: 10.1016/J.JACI.2008.09.017
  14. Cromwell O, Häfner D, Nandy A. Recombinant allergens for specific immunotherapy. J Allergy Clin Immunol. 2011;127(4): 865–872. doi: 10.1016/J.JACI.2011.01.047
  15. Weghofer M, Grote M, Resch Y, et al. Identification of Der p 23, a peritrophin-like protein, as a new major dermatophagoides pteronyssinus allergen associated with the peritrophic matrix of mite fecal pellets. J Immunol. 2013;190(7):3059–3067. doi: 10.4049/JIMMUNOL.1202288
  16. Bonertz A, Mahler V, Vieths S. New guidance on the regulation of allergen products: key aspects and outcomes. Curr Opin Allergy Clin Immunol. 2020;20(6):624–630. doi: 10.1097/ACI.0000000000000687
  17. Sastre J, Rodríguez F, Campo P, et al. Adverse reactions to immunotherapy are associated with different patterns of sensitization to grass allergens. Allergy. 2015;70(5):598–600. doi: 10.1111/ALL.12575
  18. Valenta R, Twaroch T, Swoboda I. Component-resolved diagnosis to optimize allergen-specific immunotherapy in the mediterranean area. J Investig Allergol Clin Immunol. 2007;17(Suppl 1):88−92.
  19. Shamji M, Kappen J, Akdis M, et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. Allergy. 2017;72(8):1156–1173. doi: 10.1111/ALL.13138

补充文件

附件文件
动作
1. JATS XML

版权所有 © Pharmarus Print Media, 2022

##common.cookie##